| HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study. | |
| | |
MedLine Citation:
|
PMID: 20636227 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The primary endpoint in our study was to investigate the effect of a red yeast rice (RYR) product on plasma lipids. DESIGN: A randomized, double-blind, placebo controlled study was performed. Patients were randomized to either RYR (HypoCol, 4 capsules/day) (n=22) or placebo (n=20) for 16 weeks. Inclusion criteria were male or female, 18-75 years, LDL-cholesterol between 3.0 and 6.0 mmol/L, fasting triglyceride level less than 4.5 mmol/L. RESULTS: Patients receiving RYR experienced a significant reduction in LDL-cholesterol (23.0%) and total cholesterol (15.5%) compared to placebo after 16 weeks of treatment (p<0.001). CONCLUSION: The tested red yeast rice product demonstrated a significant cholesterol lowering effect compared to placebo, and was well tolerated in this Caucasian population. |
| | |
Authors:
|
Martin Prøven Bogsrud; Leiv Ose; Gisle Langslet; Inger Ottestad; Ellen Charlotte Strøm; Tor-Arne Hagve; Kjetil Retterstøl |
Related Documents
:
|
17701167 - Interaction between a commercially available st. john's wort product (movina) and atorv... 8210967 - Effectiveness of low-dose lovastatin combined with low-dose colestipol in moderate to s... 18271497 - Effects of long-term dietary intake of magnesium on rat liver transcriptome. 18946207 - Changes of plasma lipids during weight reduction in females depends on apoa5 variants. 16119077 - Performance, feeding behaviour and microbial diversity in weaned piglets fed liquid die... 458497 - Growth, appetite, sequence of pathological signs and survival following the induction o... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Scandinavian cardiovascular journal : SCJ Volume: 44 ISSN: 1651-2006 ISO Abbreviation: Scand. Cardiovasc. J. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-19 Completed Date: 2010-11-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9708377 Medline TA: Scand Cardiovasc J Country: England |
Other Details:
|
Languages: eng Pagination: 197-200 Citation Subset: IM |
Affiliation:
|
Lipid Clinic, Rikshospitalet, Oslo University Hospital, Oslo, Norway. martin.proven.bogsrud@rikshospitalet.no |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00114855 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Biological Markers / blood Biological Products / therapeutic use* Blood Glucose / metabolism C-Reactive Protein / metabolism Cholesterol / blood* Cholesterol, LDL / blood Dietary Supplements* Double-Blind Method Down-Regulation Female Hemoglobin A, Glycosylated / metabolism Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Hypercholesterolemia / blood, drug therapy* Male Middle Aged Norway Time Factors Treatment Outcome Triglycerides / blood Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Biological Products; 0/Blood Glucose; 0/Cholesterol, LDL; 0/Hemoglobin A, Glycosylated; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Triglycerides; 0/red yeast rice; 57-88-5/Cholesterol; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: High or low risk coronary patients - who gets the highest priority?
Next Document: A pilot study of salt and water restriction in patients with chronic heart failure.